Journal article
The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK
Abstract
BACKGROUND: Real-world prescription pathways leading to triple therapy (TT) (inhaled corticosteroid [ICS] plus long-acting β2-agonist bronchodilator [LABA] plus long-acting muscarinic antagonist) differ from Global initiative for chronic Obstructive Lung Disease [GOLD] and National Institute for Health and Care Excellence treatment recommendations. This study sets out to identify COPD patients without asthma receiving TT, and determine the …
Authors
Brusselle G; Price D; Gruffydd-Jones K; Miravitlles M; Keininger DL; Stewart R; Baldwin M; Jones RC
Journal
International Journal of Chronic Obstructive Pulmonary Disease, Vol. 10, No. 0, pp. 2207–2217
Publisher
Taylor & Francis
Publication Date
October 15, 2015
DOI
10.2147/copd.s91694
ISSN
1176-9106
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAgedBronchodilator AgentsDrug Therapy, CombinationFemaleGuideline AdherenceHumansMaleMiddle AgedMuscarinic AntagonistsPractice Patterns, Physicians'Primary Health CarePulmonary Disease, Chronic ObstructiveRetrospective StudiesSeverity of Illness IndexUnited Kingdom